Matches in DBpedia 2016-04 for { ?s ?p "Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Radequinil abstract "Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.".
- Q7280124 abstract "Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.".
- Radequinil comment "Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.".
- Q7280124 comment "Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.".